These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 15780613)

  • 1. Novel and potent cyclic cyanamide-based cathepsin K inhibitors.
    Deaton DN; Hassell AM; McFadyen RB; Miller AB; Miller LR; Shewchuk LM; Tavares FX; Willard DH; Wright LL
    Bioorg Med Chem Lett; 2005 Apr; 15(7):1815-9. PubMed ID: 15780613
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel, potent P2-P3 pyrrolidine derivatives of ketoamide-based cathepsin K inhibitors.
    Barrett DG; Catalano JG; Deaton DN; Hassell AM; Long ST; Miller AB; Miller LR; Ray JA; Samano V; Shewchuk LM; Wells-Knecht KJ; Willard DH; Wright LL
    Bioorg Med Chem Lett; 2006 Mar; 16(6):1735-9. PubMed ID: 16376075
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel purine nitrile derived inhibitors of the cysteine protease cathepsin K.
    Altmann E; Cowan-Jacob SW; Missbach M
    J Med Chem; 2004 Nov; 47(24):5833-6. PubMed ID: 15537340
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acyclic cyanamide-based inhibitors of cathepsin K.
    Barrett DG; Deaton DN; Hassell AM; McFadyen RB; Miller AB; Miller LR; Payne JA; Shewchuk LM; Willard DH; Wright LL
    Bioorg Med Chem Lett; 2005 Jun; 15(12):3039-43. PubMed ID: 15896958
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure-based design of cathepsin K inhibitors containing a benzyloxy-substituted benzoyl peptidomimetic.
    Thompson SK; Smith WW; Zhao B; Halbert SM; Tomaszek TA; Tew DG; Levy MA; Janson CA; DAlessio KJ; McQueney MS; Kurdyla J; Jones CS; DesJarlais RL; Abdel-Meguid SS; Veber DF
    J Med Chem; 1998 Oct; 41(21):3923-7. PubMed ID: 9767629
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design of potent, selective, and orally bioavailable inhibitors of cysteine protease cathepsin k.
    Tavares FX; Boncek V; Deaton DN; Hassell AM; Long ST; Miller AB; Payne AA; Miller LR; Shewchuk LM; Wells-Knecht K; Willard DH; Wright LL; Zhou HQ
    J Med Chem; 2004 Jan; 47(3):588-99. PubMed ID: 14736240
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Conformationally constrained 1,3-diamino ketones: a series of potent inhibitors of the cysteine protease cathepsin K.
    Marquis RW; Yamashita DS; Ru Y; LoCastro SM; Oh HJ; Erhard KF; DesJarlais RL; Head MS; Smith WW; Zhao B; Janson CA; Abdel-Meguid SS; Tomaszek TA; Levy MA; Veber DF
    J Med Chem; 1998 Sep; 41(19):3563-7. PubMed ID: 9733481
    [No Abstract]   [Full Text] [Related]  

  • 8. Identification of a potent and selective non-basic cathepsin K inhibitor.
    Li CS; Deschenes D; Desmarais S; Falgueyret JP; Gauthier JY; Kimmel DB; Léger S; Massé F; McGrath ME; McKay DJ; Percival MD; Riendeau D; Rodan SB; Thérien M; Truong VL; Wesolowski G; Zamboni R; Black WC
    Bioorg Med Chem Lett; 2006 Apr; 16(7):1985-9. PubMed ID: 16413777
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dioxo-triazines as a novel series of cathepsin K inhibitors.
    Rankovic Z; Cai J; Fradera X; Dempster M; Mistry A; Mitchell A; Long C; Hamilton E; King A; Boucharens S; Jamieson C; Gillespie J; Cumming I; Uitdehaag J; van Zeeland M
    Bioorg Med Chem Lett; 2010 Mar; 20(5):1488-90. PubMed ID: 20153187
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 4-Aminophenoxyacetic acids as a novel class of reversible cathepsin K inhibitors.
    Shinozuka T; Shimada K; Matsui S; Yamane T; Ama M; Fukuda T; Taki M; Naito S
    Bioorg Med Chem Lett; 2006 Mar; 16(6):1502-5. PubMed ID: 16380250
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acyclic, orally bioavailable ketone-based cathepsin K inhibitors.
    Barrett DG; Catalano JG; Deaton DN; Long ST; McFadyen RB; Miller AB; Miller LR; Samano V; Tavares FX; Wells-Knecht KJ; Wright LL; Zhou HQ
    Bioorg Med Chem Lett; 2007 Jan; 17(1):22-7. PubMed ID: 17157021
    [TBL] [Abstract][Full Text] [Related]  

  • 12. P2-P3 conformationally constrained ketoamide-based inhibitors of cathepsin K.
    Barrett DG; Boncek VM; Catalano JG; Deaton DN; Hassell AM; Jurgensen CH; Long ST; McFadyen RB; Miller AB; Miller LR; Payne JA; Ray JA; Samano V; Shewchuk LM; Tavares FX; Wells-Knecht KJ; Willard DH; Wright LL; Zhou HQ
    Bioorg Med Chem Lett; 2005 Aug; 15(15):3540-6. PubMed ID: 15982880
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potent and selective P2-P3 ketoamide inhibitors of cathepsin K with good pharmacokinetic properties via favorable P1', P1, and/or P3 substitutions.
    Barrett DG; Catalano JG; Deaton DN; Hassell AM; Long ST; Miller AB; Miller LR; Shewchuk LM; Wells-Knecht KJ; Willard DH; Wright LL
    Bioorg Med Chem Lett; 2004 Oct; 14(19):4897-902. PubMed ID: 15341947
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Arylaminoethyl amides as noncovalent inhibitors of cathepsin S. Part 2: Optimization of P1 and N-aryl.
    Alper PB; Liu H; Chatterjee AK; Nguyen KT; Tully DC; Tumanut C; Li J; Harris JL; Tuntland T; Chang J; Gordon P; Hollenbeck T; Karanewsky DS
    Bioorg Med Chem Lett; 2006 Mar; 16(6):1486-90. PubMed ID: 16412634
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 3,4-disubstituted azetidinones as selective inhibitors of the cysteine protease cathepsin K. Exploring P3 elements for potency and selectivity.
    Setti EL; Davis D; Janc JW; Jeffery DA; Cheung H; Yu W
    Bioorg Med Chem Lett; 2005 Mar; 15(5):1529-34. PubMed ID: 15713422
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantitative evaluation of each catalytic subsite of cathepsin B for inhibitory activity based on inhibitory activity-binding mode relationship of epoxysuccinyl inhibitors by X-ray crystal structure analyses of complexes.
    Watanabe D; Yamamoto A; Tomoo K; Matsumoto K; Murata M; Kitamura K; Ishida T
    J Mol Biol; 2006 Oct; 362(5):979-93. PubMed ID: 16950396
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Orally bioavailable small molecule ketoamide-based inhibitors of cathepsin K.
    Barrett DG; Catalano JG; Deaton DN; Long ST; Miller LR; Tavares FX; Wells-Knecht KJ; Wright LL; Zhou HQ
    Bioorg Med Chem Lett; 2004 May; 14(10):2543-6. PubMed ID: 15109647
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Benzodioxocin-3-ones and N-acyl-3-amino-3-buten-2-ones: novel classes of cathepsin K cysteine protease inhibitors.
    Yamashita DS; Xie R; Lin H; Wang B; Shi SD; Quinn CJ; Hemling ME; Hissong C; Tomaszek TA; Veber DF
    J Pept Res; 2004 Mar; 63(3):265-9. PubMed ID: 15049838
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A structural screening approach to ketoamide-based inhibitors of cathepsin K.
    Barrett DG; Catalano JG; Deaton DN; Long ST; McFadyen RB; Miller AB; Miller LR; Wells-Knecht KJ; Wright LL
    Bioorg Med Chem Lett; 2005 May; 15(9):2209-13. PubMed ID: 15837295
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dipeptide-derived nitriles containing additional electrophilic sites: potentially irreversible inhibitors of cysteine proteases.
    Löser R; Gütschow M
    J Enzyme Inhib Med Chem; 2009 Dec; 24(6):1245-52. PubMed ID: 19912058
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.